GLP-1 receptor agonists for Alzheimer's disease: Lessons from trials and translational challenges.
Where this comes from
- Record sourced from PubMed, PMID 42612619.
- Also identified by DOI 10.1016/j.xcrm.2026.102918.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alzheimer's disease (AD) is a multifactorial disorder that requires combined therapeutic strategies beyond amyloid clearance. Although GLP-1 receptor agonists show strong mechanistic rationale and supportive epidemiological signals for neuroprotection, large randomized trials in symptomatic AD have yielded negative clinical outcomes and do not support the therapeutic use in AD.
Medical subject headings
- Alzheimer Disease
- Glucagon-Like Peptide-1 Receptor Agonists
- Neuroprotective Agents